Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary PerspectivesNEUROLOGY AND THERAPYIF4.82024-01-112OAAI
Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis studyCTS-CLINICAL AND TRANSLATIONAL SCIENCEIF2.82022-09-3010OA
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension StudiesADVANCES IN THERAPYIF42021-08-0924OAAI
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studiesMULTIPLE SCLEROSIS JOURNALIF52021-05-1017OAAI
Facing the urgency of therapies for progressive MS - a Progressive MS Alliance proposalNATURE REVIEWS NEUROLOGYIF33.12021-01-2224PREAI
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive ReviewDRUGSIF14.42020-11-2843OAAI
Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of SafetyDRUG SAFETYIF3.82020-05-2325OAAI
Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets in the clarity and clarity extension studiesJOURNAL OF THE NEUROLOGICAL SCIENCESIF3.22019-10-010OAAI
THE EFFECT OF CLADRIBINE TABLETS ON DELAYING THE TIME TO CONVERSION TO CLINICALLY DEFINITE MULTIPLE SCLEROSIS (MS) OR MCDONALD MS IS CONSISTENT ACROSS SUBGROUPS IN THE ORACLE-MS STUDYJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52019-07-290OAAI
EFFICACY AND SAFETY OF THE BRUTON'S TYROSINE KINASE INHIBITOR EVOBRUTINIB (M2951) IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS OVER 48 WEEKS: A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDYJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52019-07-290OAAI
CLADRIBINE TABLETS WERE ASSOCIATED WITH RAPID ONSET OF IMPROVEMENTS IN MRI OUTCOMES IN THE ORACLE-MS TRIALJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52019-07-290OAAI
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple SclerosisNEW ENGLAND JOURNAL OF MEDICINEIF78.52019-06-20236OAAI
Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosisBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32019-05-064OAAI
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple SclerosisCLINICAL THERAPEUTICSIF3.62019-02-0124OAAI
CLADRIBINE TABLETS EFFECTS ON LYMPHOCYTES IN MS PATIENTSJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52018-09-130PREAI
YEARLY LYMPHOPENIA RATES IN CLADRIBINE TABLETS-TREATED RMS PATIENTSJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52018-09-130PRE
CLADRIBINE TABLETS IN CLARITY PATIENTS WITH HIGH DISEASE ACTIVITY MSJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52018-09-130PREAI
CLARITY: MRI OUTCOMES IN HIGH DISEASE ACTIVITY RELAPSING MSJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52018-09-130PRE
INFECTIONS DURING GRADE 3/4 LYMPHOPENIA WITH CLADRIBINE TABLETSJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRYIF7.52018-09-130PRE
Cladribine tablets added to IFN-β in active relapsing MS The ONWARD studyNEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATIONIF7.52018-09-0148OAAI